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E
ven though studies demonstrate im-
proved insulin resistance following
alterationsinHIVantiretroviralther-
apy (ART) (1), there are no published re-
ports documenting reversal of diabetes.
We report on one HIV-infected youth
who met criteria for diabetes and one
HIV-infected young adult with im-
paired glucose tolerance (IGT), both of
whom experienced signiﬁcant improve-
ments at 1 and 2 years after ART modi-
ﬁcation.
Case 1 is a 15-year-old Caucasian
male with vertically acquired HIV. He
had12yearsofcumulativeARTexposure.
Past medical history included Burkitt’s
lymphoma in remission for 5 years, tran-
sient IGT, and adrenal insufﬁciency
related to megestrol acetate at age 10, hy-
pertriglyceridemia treated with fenoﬁ-
brate, and lipoatrophy. At age 15 years
and 9 months, he was on lamivudine/
stavudine/tenofovir/lopinavir/ritonavir
(startedatage11years)withwell-controlled
HIV. Fasting glucose was 98 mg/dL, and
2-h postchallenge glucose was 96 mg/dL.
At age 16 years and 3 months, fasting
glucose was 139 mg/dL. At age 16 years
and 7 months, his ART changed for con-
cerns of diabetes and lipodystrophy.
Tenofovir and stavudine were removed,
andabacavirwasadded.Onemonthlater,
hehadtotalcholesterolof243mg/dLand
triglycerides of 477 mg/dL. Diabetes was
conﬁrmed by oral glucose tolerance test
2-h glucose measurement of 230 mg/dL.
As a result of dyslipidemia and di-
abetes, a further change in ART was
recommended. At age 17 years and 6
months, lopinavir/ritonavir was replaced
with ritonavir-boosted atazanavir. At age
17 years 8 and months, his lipid proﬁle
was markedly improved, his fasting glu-
cose was 95 mg/dL, and his 2-h glucose
measurement was 121 mg/dL. Diabetes
was not present at subsequent glucose
testing at age 18 years 2 months.
Case 2 is a 24-year-old African Amer-
icanmalewithtrisomy21andtransfusion-
acquired HIV. He had been on continuous
ART since age 9 years. His medical history
is signiﬁcant for an atrioventricular canal
repair,chronicthrombocytopenia,andlip-
oatrophy.
At age 24 years and 10 months, he
was on stavudine/lamivudine (started at
age16years).Fastingglucosewas94mg/dL,
and 2-h postchallenge glucose was 194
mg/dL. He was symptomatic of hypergly-
cemia with excess thirst and urination,
and had hypertriglyceridemia and low
HDL. His ART regimen was modiﬁed at
age 24 years and 11 months; stavudine
was discontinued. The new regimen was
lamivudine/abacavir/nevirapine. By age
25 years and 11 months, his 2-h glucose
had normalized (91 mg/dL). His lipid
panel and lipoatrophy improved, symp-
toms of diabetes had resolved, and HIV
remained well controlled. During follow-
uptestingatage27yearsand9monthshis
fasting and 2-h glucose measurements re-
mained normal.
This report provides insight into the
potential inﬂuence of ART exposure and
ART modiﬁcation on metabolic distur-
bances in HIV (2). De Wit et al. (3) re-
ported an association between diabetes
and cumulative stavudine, didanosine,
and zidovudine exposure. Both cases re-
portedherehadprolongedexposuretoall
threeagentsandwereonstavudineatpre-
sentation. Here, following alterations in
ART regimens, the patients no longer
metcriteriafordiabetesorIGTbyglucose
tolerancetesting.Incase1,thereplacement
of lopinavir/ritonavir with atazanavir/
ritonavir may have contributed to im-
provements in both glucose and lipid
parameters (1).
In summary, our ﬁndings show
t h a tm o d i f y i n gA R Tm a ya m e l i o r a t e
metabolic abnormaliti e ss u c ha sd i a b e -
tes in patients with well-controlled
HIV infection. This report highlights the
need for close monitoring of metabolic
complications and consideration of ART
adjustments when feasible.
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